Compare Mesoblast Limited (MESO) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Health Care Select Sector SPDR Fund — how do they compare? Mesoblast Limited trades at $16.79 (market cap $2.21B), while Health Care Select Sector SPDR Fund trades at $168.55. The key difference: Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | XLV | |
|---|---|---|
Market Cap | $2.21B | — |
Sector | Technology | — |
52-Week High | $20.96 | $168.44 |
52-Week Low | $12.88 | $131.16 |
Enterprise Value | $2.21B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.82, up 0.84% with bullish technical signals from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144.33% net income margin. Recent developments include positive Phase 3 trial progress and BLA filing for heart failure treatment, supported by analyst consensus leaning bullish with 45% buy ratings.
MESO presents a high-risk, high-reward opportunity with promising commercial traction offset by significant losses. Investment thesis hinges on successful pipeline development and profitability turnaround, while risks include clinical trial outcomes, regulatory approvals, and sustained cash burn requiring careful monitoring of execution milestones.
XLV, the Health Care Select Sector SPDR ETF, trades at $167.93, down 0.3% on the day, with a bullish technical signal driven by moving averages. The ETF offers broad healthcare exposure with a low expense ratio of 0.08% and a trailing dividend yield of 1.6%, positioning it as a cost-effective defensive play amid market volatility. Recent news highlights strong sector inflows and defensive demand, with earnings from key holdings like UnitedHealth showing resilience despite Medicaid pressures.
The outlook for XLV is positive, supported by its defensive characteristics and institutional interest, though risks include regulatory pressures and sector-specific volatility. Investors may find value in its diversification and steady performance, but should monitor healthcare policy developments and earnings trends for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
